Goserelin  (Synonyms: ICI 118630)

Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer^[1][2].

GnRH^[1]

Goserelin (1 nM-1 mM; 48-72 hours) promots EOC cell apoptosis^[1].
Goserelin (100 μM; 24-72 hours) regulates the expression of human apoptosis-related genes in SKOV3-ip cells^[1].
Goserelin (100 μM; 24-72 hours) influences EOC cell apoptosis by upregulating FOXO1 through the PI3K/AKT signaling pathway^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Goserelin (100 μg; s.c.; daily; for 19 days) significantly increases the proportion of apoptotic cells in the subcutaneous xenograft tumors^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1269.41

C₅₉H₈₄N₁₈O₁₄

65807-02-5

{Glp}-His-Trp-Ser-Tyr-Ser(OtBu)-Leu-Arg-Pro-{Hydrazinecarboxamide}

{Glp}-HWSY-Ser(OtBu)-LRP-{Hydrazinecarboxamide}

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Ning Zhang, et al. Goserelin promotes the apoptosis of epithelial ovarian cancer cells by upregulating forkhead box O1 through the PI3K/AKT signaling pathway. Oncol Rep. 2018 Mar; 39(3): 1034–1042.  [Content Brief]

  [2]. Halle C F Moore, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015 Mar 5;372(10):923-32.  [Content Brief]